Tuberculosis and Respiratory Diseases最新文献_第6页

Inhaled Corticosteroids May Not Affect the Clinical Outcomes of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. 吸入皮质类固醇可能不会影响慢性阻塞性肺病患者肺炎的临床疗效。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2024-07-01 Epub Date: 2024-02-19 DOI: 10.4046/trd.2023.0176

Min-Seok Chang, In-So Cho, Iseul Yu, Sunmin Park, Seok Jeong Lee, Suk Joong Yong, Won-Yeon Lee, Sang-Ha Kim, Ji-Ho Lee

{"title":"Inhaled Corticosteroids May Not Affect the Clinical Outcomes of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.","authors":"Min-Seok Chang, In-So Cho, Iseul Yu, Sunmin Park, Seok Jeong Lee, Suk Joong Yong, Won-Yeon Lee, Sang-Ha Kim, Ji-Ho Lee","doi":"10.4046/trd.2023.0176","DOIUrl":"10.4046/trd.2023.0176","url":null,"abstract":"Background: Although inhaled corticosteroids (ICS) is reportedly associated with a higher risk of pneumonia in chronic obstructive pulmonary disease (COPD), the clinical implications of ICS have not been sufficiently verified to determine their effect on the prognosis of pneumonia.Methods: The electronic health records of patients hospitalized for pneumonia with underlying COPD were retrospectively reviewed. Pneumonia was confirmed using chest radiography or computed tomography. The clinical outcomes of pneumonia in patients with COPD who received ICS and those who received long-acting bronchodilators other than ICS were compared.Results: Among the 255 hospitalized patients, 89 met the inclusion criteria. The numbers of ICS and non-ICS users were 46 and 43, respectively. The CURB-65 (confusion, uremia, respiratory rate, blood pressure, age ≥65 years) scores at the initial presentation of pneumonia were comparable between the two groups. The proportions of patients with multilobar infiltration, pleural effusion, and complicated pneumonia in the radiological studies did not vary between the two groups. Additionally, the defervescence time, proportion of mechanical ventilation, intensive care unit admission, length of hospital stays, and mortality rate at 30 and 90 days were not significantly different between the two groups. ICS use and blood eosinophils count were not associated with all pneumonia outcomes and mortality in multivariate analyses.Conclusion: The clinical outcomes of pneumonia following ICS use in patients with COPD did not differ from those in patients treated without ICS. Thus, ICS may not contribute to the severity and outcomes of pneumonia in patients with COPD.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"319-328"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proposed Etiotypes for Chronic Obstructive Pulmonary Disease: Controversial Issues. 慢性阻塞性肺病的拟议病因：有争议的问题。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2024-07-01 Epub Date: 2024-02-06 DOI: 10.4046/trd.2023.0194

Sang Hyuk Kim, Ji-Yong Moon, Kyung Hoon Min, Hyun Lee

{"title":"Proposed Etiotypes for Chronic Obstructive Pulmonary Disease: Controversial Issues.","authors":"Sang Hyuk Kim, Ji-Yong Moon, Kyung Hoon Min, Hyun Lee","doi":"10.4046/trd.2023.0194","DOIUrl":"10.4046/trd.2023.0194","url":null,"abstract":"The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) revised the definition of chronic obstructive pulmonary disease (COPD) to broadly include a variety of etiologies. A new taxonomy, composed of etiotypes, aims to highlight the heterogeneity in causes and pathogenesis of COPD, allowing more personalized management strategies and emphasizing the need for targeted research to understand and manage COPD better. However, controversy arises with including some diseases under the umbrella term of COPD, as their clinical presentations and treatments differ from classical COPD, which is smoking-related. COPD due to infection (COPD-I) and COPD due to environmental exposure (COPD-P) are classifications within the new taxonomy. Some disease entities in these categories show distinct clinical features and may not benefit from conventional COPD treatments, raising questions about their classification as COPD subtypes. There is also controversy regarding whether bronchiectasis with airflow limitations should be classified as an etiotype of COPD. This article discusses controversial issues associated with the proposed etiotypes for COPD in terms of COPD-I, COPD-P, and bronchiectasis. While the updated COPD definition by GOLD 2023 is a major step towards recognizing the disease's complexity, it also raises questions about the classification of related respiratory conditions. This highlights the need for further research to improve our understanding and approach to COPD management.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"221-233"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review. 慢性阻塞性肺病的经济负担：系统回顾。

IF 2.5

Tuberculosis and Respiratory Diseases Pub Date : 2024-07-01 Epub Date: 2024-02-16 DOI: 10.4046/trd.2023.0100

Hai Quang Pham, Kiet Huy Tuan Pham, Giang Hai Ha, Tin Trung Pham, Hien Thi Nguyen, Trang Huyen Thi Nguyen, Jin-Kyoung Oh

{"title":"Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review.","authors":"Hai Quang Pham, Kiet Huy Tuan Pham, Giang Hai Ha, Tin Trung Pham, Hien Thi Nguyen, Trang Huyen Thi Nguyen, Jin-Kyoung Oh","doi":"10.4046/trd.2023.0100","DOIUrl":"10.4046/trd.2023.0100","url":null,"abstract":"Globally, providing evidence on the economic burden of chronic obstructive pulmonary disease (COPD) is becoming essential as it assists the health authorities to efficiently allocate resources. This study aimed to summarize the literature on economic burden evidence for COPD from 1990 to 2019. This study examined the economic burden of COPD through a systematic review of studies from 1990 to 2019. A search was done in online databases, including Web of Science, PubMed/Medline, Scopus, and the Cochrane Library. After screening 12,734 studies, 43 articles that met the inclusion criteria were identified. General study information and data on direct, indirect, and intangible costs were extracted and converted to 2018 international dollars (Int$). Findings revealed that the total direct costs ranged from Int$ 52.08 (India) to Int$ 13,776.33 (Canada) across 16 studies, with drug costs rannging from Int$ 70.07 (Vietnam) to Int$ 8,706.9 (China) in 11 studies. Eight studies explored indirect costs, while one highlighted caregivers' direct costs at approximately Int$ 1,207.8 (Greece). This study underscores the limited research on COPD caregivers' economic burdens, particularly in developing countries, emphasizing the importance of increased research support, particularly in high-resource settings. This study provides information about the demographics and economic burden of COPD from 1990 to 2019. More strategies to reduce the frequency of hospital admissions and acute care services should be implemented to improve the quality of COPD patients' lives and reduce the disease's rising economic burden.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"234-251"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sarcopenia in Outcome in Chronic Obstructive Pulmonary Disease: Is the Tip of the Iceberg? 慢性阻塞性肺病患者的Sarcopenia结局：这只是冰山一角吗？

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-11-01 DOI: 10.4046/trd.2023.0146

Hulya Sungurtekin, Ugur Sungurtekin, Antonio M Esquinas

引用次数: 0

Progressive Pulmonary Fibrosis: Where Are We Now? 进行性肺纤维化：我们现在在哪里？

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-18 DOI: 10.4046/trd.2023.0119

Hyung Koo Kang, Jin Woo Song

{"title":"Progressive Pulmonary Fibrosis: Where Are We Now?","authors":"Hyung Koo Kang, Jin Woo Song","doi":"10.4046/trd.2023.0119","DOIUrl":"10.4046/trd.2023.0119","url":null,"abstract":"Interstitial lung diseases (ILDs) are a diverse collection of lung disorders sharing similar features, such as inflammation and fibrosis. The diagnosis and management of ILD require a multidisciplinary approach using clinical, radiological, and pathological evaluation. Progressive pulmonary fibrosis (PPF) is a distinct form of progressive and fibrotic disease, occurring in ILD cases other than in idiopathic pulmonary fibrosis (IPF). It is defined based on clinical symptoms, lung function, and chest imaging, regardless of the underlying condition. The progression to PPF must be monitored through a combination of pulmonary function tests (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide), an assessment of symptoms, and computed tomography scans, with regular follow-up. Although the precise mechanisms of PPF remain unclear, there is evidence of shared pathogenetic mechanisms with IPF, contributing to similar disease behavior and worse prognosis compared to non-PPF ILD. Pharmacological treatment of PPF includes immunomodulatory agents to reduce inflammation and the use of antifibrotics to target progressive fibrosis. Nintedanib, a known antifibrotic agent, was found to be effective in slowing IPF progression and reducing the annual rate of decline in FVC among patients with PPF compared to placebos. Nonpharmacological treatment, including pulmonary rehabilitation, supplemental oxygen therapy, and vaccination, also play important roles in the management of PPF, leading to comprehensive care for patients with ILD. Although there is currently no cure for PPF, there are treatments that can help slow the progression of the disease and improve quality of life.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"123-133"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid. 对氟喹诺酮类药物耐药的 XDR 前期肺结核患者的治疗结果：对德拉马尼的影响

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-18 DOI: 10.4046/trd.2023.0188

Oki Nugraha Putra, Telly Purnamasari

引用次数: 0

Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors' Reply. 对氟喹诺酮类药物产生耐药性的耐多药结核病的治疗结果：对地拉马尼的影响--作者回复。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.4046/trd.2024.0010

Saerom Kim, Jeongha Mok

引用次数: 0

Oscillometry-Defined Small Airway Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. 慢性阻塞性肺病患者的振荡测定定义的小气道功能障碍。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2024-01-16 DOI: 10.4046/trd.2023.0139

Amit K Rath, Dibakar Sahu, Sajal De

{"title":"Oscillometry-Defined Small Airway Dysfunction in Patients with Chronic Obstructive Pulmonary Disease.","authors":"Amit K Rath, Dibakar Sahu, Sajal De","doi":"10.4046/trd.2023.0139","DOIUrl":"10.4046/trd.2023.0139","url":null,"abstract":"Background: The prevalence of small airway dysfunction (SAD) in patients with chronic obstructive pulmonary disease (COPD) across different ethnicities is poorly understood. This study aimed to estimate the prevalence of SAD in stable COPD patients.Methods: We conducted a cross-sectional study of 196 consecutive stable COPD patients. We measured pre- and post-bronchodilator (BD) lung function and respiratory impedance. The severity of COPD and lung function abnormalities was graded in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. SAD was defined as either difference in whole-breath resistance at 5 and 19 Hz > upper limit of normal or respiratory system reactance at 5 Hz < lower limit of normal.Results: The cohort consisted of 95.9% men, with an average age of 66.3 years. The mean forced expiratory volume 1 second (FEV1) % predicted was 56.4%. The median COPD assessment test (CAT) scores were 14. The prevalence of post-BD SAD across the GOLD grades 1 to 4 was 14.3%, 51.1%, 91%, and 100%, respectively. The post-BD SAD and expiratory flow limitation at tidal breath (EFLT) were present in 62.8% (95% confidence interval [CI], 56.1 to 69.9) and 28.1% (95% CI, 21.9 to 34.2), respectively. COPD patients with SAD had higher CAT scores (15.5 vs. 12.8, p<0.01); poor lung function (FEV1% predicted 46.6% vs. 72.8%, p<0.01); lower diffusion capacity for CO (4.8 mmol/min/kPa vs. 5.6 mmol/min/kPa, p<0.01); hyperinflation (ratio of residual volume to total lung capacity % predicted: 159.7% vs. 129%, p<0.01), and shorter 6-minute walk distance (367.5 m vs. 390 m, p=0.02).Conclusion: SAD is present across all severities of COPD. The prevalence of SAD increases with disease severity. SAD is associated with poor lung function and higher symptom burden. Severe SAD is indicated by the presence of EFLT.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"165-175"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between Antacid Exposure and Risk of Interstitial Lung Diseases. 抗酸剂接触与间质性肺病风险之间的关系

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-19 DOI: 10.4046/trd.2023.0093

Soohyun Bae, Gjustina Loloci, Dong Yoon Lee, Hye Jin Jang, Jihyeon Jeong, Won-Il Choi

{"title":"Association between Antacid Exposure and Risk of Interstitial Lung Diseases.","authors":"Soohyun Bae, Gjustina Loloci, Dong Yoon Lee, Hye Jin Jang, Jihyeon Jeong, Won-Il Choi","doi":"10.4046/trd.2023.0093","DOIUrl":"10.4046/trd.2023.0093","url":null,"abstract":"Background: The mechanisms leading to lung fibrosis are still under investigation. This study aimed to demonstrate whether antacids could prevent the development of interstitial lung disease (ILD).Methods: This population-based longitudinal cohort study was conducted between January 2006 and December 2010 in South Korea. Eligible subjects were ≥40 years of age, exposed to proton pump inhibitors (PPI)±histamine-2 receptor antagonists (H-2 blockers) or H-2 blockers only, and had no history of ILD between 2004 and 2005. Exposure to antacids was defined as the administration of either PPI or H-2 receptor antagonists for >14 days, whereas underexposure was defined as antacid treatment administered for less than 14 days. Newly developed ILDs, including idiopathic pulmonary fibrosis (IPF), were counted during the 5-year observation period. The association between antacid exposure and ILD development was evaluated using adjusted Cox regression models with variables, such as age, sex, smoking history, and comorbidities.Results: The incidence rates of ILD with/without antacid use were 43.2 and 33.8/100,000 person-years, respectively and those of IPF were 14.9 and 22.9/100,000 person-years, respectively. In multivariable analysis, exposure to antacid before the diagnosis of ILD was independently associated with a reduced development of ILD (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45 to 0.71; p<0.001), while antacid exposure was not associated with development of IPF (HR, 0.88; 95% CI, 0.72 to 1.09; p=0.06).Conclusion: Antacid exposure may be independently associated with a decreased risk of ILD development.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"185-193"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial Lung Abnormality in Asian Population. 亚洲人的肺间质异常。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-19 DOI: 10.4046/trd.2023.0117

Gong Yong Jin

{"title":"Interstitial Lung Abnormality in Asian Population.","authors":"Gong Yong Jin","doi":"10.4046/trd.2023.0117","DOIUrl":"10.4046/trd.2023.0117","url":null,"abstract":"Interstitial lung abnormalities (ILAs) are radiologic abnormalities found incidentally on chest computed tomography (CT) that can be show a wide range of diseases, from subclinical lung fibrosis to early pulmonary fibrosis including definitive usual interstitial pneumonia. To clear up confusion about ILA, the Fleischner society published a position paper on the definition, clinical symptoms, increased mortality, radiologic progression, and management of ILAs based on several Western cohorts and articles. Recently, studies on long-term outcome, risk factors, and quantification of ILA to address the confusion have been published in Asia. The incidence of ILA was 7% to 10% for Westerners, while the prevalence of ILA was about 4% for Asians. ILA is closely related to various respiratory symptoms or increased rate of treatment-related complication in lung cancer. There is little difference between Westerners and Asians regarding the clinical importance of ILA. Although the role of quantitative CT as a screening tool for ILA requires further validation and standardized imaging protocols, using a threshold of 5% in at least one zone demonstrated 67.6% sensitivity, 93.3% specificity, and 90.5% accuracy, and a 1.8% area threshold showed 100% sensitivity and 99% specificity in South Korea. Based on the position paper released by the Fleischner society, I would like to report how much ILA occurs in the Asian population, what the prognosis is, and review what management strategies should be pursued in the future.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"134-144"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0